| Autor: |
de Castro Pereira, Carlos Alberto, Antonio Baddini-Martinez, José, Baldi, Bruno Guedes, de Oliveira Jezler, Sérgio Fernandes, Sperb Rubin, Adalberto, Rufino Alves, Rogerio Lopes, Zonzin, Gilmar Alves, Quaresma, Manuel, Trampisch, Matthias, Rabahi, Marcelo Fouad |
| Zdroj: |
Brazilian Journal of Pulmonology / Jornal Brasileiro de Pneumologia; Sep/Oct2019, Vol. 45 Issue 5, p1-7, 7p, 2 Diagrams, 4 Charts |
| Abstrakt: |
Objective: Clinical trials have shown that nintedanib 150 mg twice daily (bid) reduces disease progression in patients with idiopathic pulmonary fibrosis (IPF), with an adverse event profile that is manageable for most patients. Prior to the approval of nintedanib as a treatment for IPF in Brazil, an expanded access program (EAP) was initiated to provide early access to treatment and to evaluate the safety and tolerability of nintedanib in this patient population. Methods: Patients with a diagnosis of IPF within the previous five years, forced vital capacity (FVC) ≥ 50% predicted and diffusing capacity of the lungs for carbon monoxide (DLco) 30% to 79% predicted were eligible to participate in the EAP. Patients received nintedanib 150 mg bid open-label. Safety assessments included adverse events leading to permanent discontinuation of nintedanib and serious adverse events. Results: The EAP involved 57 patients at eight centers. Most patients were male (77.2%) and white (87.7%). At baseline, mean (SD) age was 70.7 (7.5) years and FVC w as 7 0.7 ( 12.5) % p redicted. M ean ( SD) e xposure t o n intedanib w as 1 4.4 ( 6.2) months; maximum exposure was 22.0 months. The most frequently reported adverse events considered by the investigator to be related to nintedanib treatment were diarrhea (45 patients, 78.9%) and nausea (25 patients, 43.9%). Adverse events led to permanent discontinuation of nintedanib in 16 patients (28.1%). Sixteen patients (28.1%) had a serious adverse event. Conclusion: In the Brazilian EAP, nintedanib had an acceptable safety and tolerability profile in patients with IPF, consistent with data from clinical trials. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
